Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Bristol's Opdivo/Yervoy Combo Beats Sutent On Survival In Renal Cancer

Sep 07 2017

• By Jessica Merrill

Digital illustration of Cancer cell in colour background

Related Content

Bristol Falls Further Behind Merck In NSCLC By Pulling Early Combo Filing

Jan 20 2017

MYSTIC Misses: Devastation For AstraZeneca As Imfinzi Fails PFS Endpoint In NSCLC

Jul 27 2017

'Total Disaster' In First-Line Lung Cancer For BMS's Opdivo

Oct 10 2016

Another Opdivo Disappointment For BMS, This Time In Kidney Cancer

Aug 16 2017

Related Companies

Bristol Myers Squibb Company

Pfizer Inc.

Roche Holding AG

AstraZeneca PLC

Additional Topics

ImmunoOncology Clinical Trials Research & Development Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window